The board of Danish Pharma Equity Group has resolved to issue convertible loans of up to approximately DKK 4.1 million. In connection with the issue, previously issued convertibles totalling approximately DKK 2.9 million will be redeemed.
The new loans carry an annual interest rate of 10 percent and can be converted into shares at a price of DKK 0.10 per share. The previous loans had conversion prices of DKK 0.20 and DKK 0.12, respectively.
The conversion right may be exercised for 30 days from the beginning of the 23rd month after the loan was entered into. The company may extend the maturity by twelve months.
If the conversion right is not exercised, the loans and accrued interest will be repaid in shares at the conversion price.
The maximum increase in share capital amounts to approximately DKK 5.4 million. Existing shareholders do not have pre-emptive rights to the new shares.